Skip to main content
. Author manuscript; available in PMC: 2021 Sep 14.
Published in final edited form as: Biol Blood Marrow Transplant. 2013 Apr 30;19(7):1059–1064. doi: 10.1016/j.bbmt.2013.04.014

Table 2:

Response and outcomes to salvage treatment

Treatments N = 93 (%) CR rates (%) Median OS (months) Number, cause of death
Mild therapy
Single agent chemo (n=6):
(Clofarabine, n= 2; nelarabine, n=2; azacitidine, n=1; hydrea, n=1)
Novel therapeutic agents/ Trial Medications (n=13)
Steroids / Gentle chemo (n=2)
TKIs (n= 6)		 27 (29) 41 4 TRM (n=1)
Disease relapse
(n=25)
Intensive chemotherapy
MTX / Ara C (n= 4)
HyperCVAD / Augmented HyperCVAD24 (n=20)
MOAD25 ( n=4)
Others (n=2)		 30 (32) 27 4 TRM (n=2)
Disease relapse (n=24)
Unknown (n=1)
Radiotherapy or IT alone 6 (7) 83 3 TRM (n=1)
Disease relapse( n=4)
DLI
+ Intensive chemotherapy (n=8)
+ Mild chemotherapy (n= 3)		 11 (12) 64 6.5 TRM (n=2)
Disease relapse (n=9)
Second HSCT
+ Intensive chemotherapy (n=14)
+ Mild chemotherapy (n=5)		 19 (20) 84 10 TRM (n= 5)
Disease relapse (n=8)

OS indicates overall survival; TKIs, tyrosine kinase inhibitors; GCSF, granulocyte colony stimulating factor; MTX, methotrexate; Ara-C, cytarabine; IT, intrathecal; DLI, donor lymphocyte infusion; HSCT, hematopoietic stem cell transplantation; HyperCVAD: fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone combined with methotrexate, cytarabine; MOAD: methotrexate, vincristine, L-asparaginase and dexamethasone